SLC5A2 and urinary bladder carcinoma: This review accounted for 48 cases of bladder cancer in 28 055 participants treated with SGLT‐2 inhibitors, compared to 58 cases of bladder cancer in 20 594 participants treated with placebo or active comparators.13